Home Site Index Contact Us
  Wed, May 14, 2008 
 
 
 
 
 


ImClone Systems 2007 Oncology Product Development
Pre-
Clinical
IND
Filing
Phase
I
Phase
II
Phase
III
FDA
Appr-
oval
Phase
IV
GROWTH FACTOR BLOCKERS
Erbitux®
TARGET: EGFR
INDICATIONS:
Irinotecan refractory or intolerant metastatic colorectal cancer*
Earlier stage colorectal cancer
Non-small cell lung cancer
Head & neck cancer
Pancreatic cancer
Other
 
IMC-11F8
TARGET: EGFR
INDICATION: Solid tumors
IMC-A12
TARGET: IGF-1R
INDICATION: Solid tumors
IMC-18F1
TARGET: VEGFR-1
INDICATION: Breast, CRC
IMC-3G3
TARGET: PDGFRα
INDICATION: Prostate, breast, ovarian
ANGIOGENESIS INHIBITORS
IMC-1121b
TARGET: VEGFR-2/KDR
INDICATION: Solid and liquid tumors

*Please visit www.Erbitux.com for full U.S. prescribing information, including important safety information

Company Overview | Clinical Programs | Research | News | Investor Relations | Calendar | Careers | Product Support Program  
© 2008 ImClone Systems Incorporated